Target Price | $15.30 |
Price | $5.73 |
Potential |
167.02%
register free of charge
|
Number of Estimates | 10 |
10 Analysts have issued a price target Vir Biotechnology Inc 2026 .
The average Vir Biotechnology Inc target price is $15.30.
This is
167.02%
register free of charge
$32.55
468.06%
register free of charge
$12.12
111.52%
register free of charge
|
|
A rating was issued by 14 analysts: 13 Analysts recommend Vir Biotechnology Inc to buy, 1 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Vir Biotechnology Inc stock has an average upside potential 2026 of
167.02%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 74.21 | 11.62 |
13.89% | 84.34% | |
EBITDA Margin | -743.66% | -4,241.92% |
6.28% | 470.41% | |
Net Margin | -703.36% | -3,967.26% |
1.45% | 464.05% |
10 Analysts have issued a sales forecast Vir Biotechnology Inc 2025 . The average Vir Biotechnology Inc sales estimate is
This results in the following potential growth metrics:
7 Analysts have issued an Vir Biotechnology Inc EBITDA forecast 2025. The average Vir Biotechnology Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
11 Vir Biotechnology Inc Analysts have issued a net profit forecast 2025. The average Vir Biotechnology Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -3.83 | -3.32 |
16.56% | 13.32% | |
P/E | negative | |
EV/Sales | 16.35 |
11 Analysts have issued a Vir Biotechnology Inc forecast for earnings per share. The average Vir Biotechnology Inc EPS is
This results in the following potential growth metrics and future valuations:
Vir Biotechnology Inc...
Analyst | Rating | Action | Date |
---|---|---|---|
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 15 2025 |
Evercore ISI Group |
Locked
➜
Locked
|
Locked | Sep 03 2025 |
B of A Securities |
Locked
➜
Locked
|
Locked | Aug 27 2025 |
Raymond James |
Locked
➜
Locked
|
Locked | Jul 11 2025 |
Needham |
Locked
➜
Locked
|
Locked | May 22 2025 |
Needham |
Locked
➜
Locked
|
Locked | May 12 2025 |
Goldman Sachs |
Locked
➜
Locked
|
Locked | Apr 17 2025 |
Analyst Rating | Date |
---|---|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 15 2025 |
Locked
Evercore ISI Group:
Locked
➜
Locked
|
Sep 03 2025 |
Locked
B of A Securities:
Locked
➜
Locked
|
Aug 27 2025 |
Locked
Raymond James:
Locked
➜
Locked
|
Jul 11 2025 |
Locked
Needham:
Locked
➜
Locked
|
May 22 2025 |
Locked
Needham:
Locked
➜
Locked
|
May 12 2025 |
Locked
Goldman Sachs:
Locked
➜
Locked
|
Apr 17 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.